ZandCellZandCell
  • HOME
  • About
    • About
    • News Releases
  • Programs
  • Science
  • Apply
  • Contact
  • Login

    Lost your password?

  • 0
    Cart
  1. Home
  2. B. C. girl with leukemia seeks Christmas stem cell donor – DigitalJournal.com
  3. NEWS

NEWS

Tooth banking: Is the next wave in stem cell treatment right for you? – KCTV Kansas City

Continue reading

2017-10-19 Michael Zand NEWS

5 things you need to know now – The Week Magazine

5 things you need to know nowThe Week MagazineThe Food and Drug Administration on Wednesday approved a one-time treatment for lymphoma in adults, only the second time a gene therapy for blood cancer has been given the OK in the United States. This is t… Continue reading

2017-10-19 Michael Zand NEWS

FDA approves second gene-altering treatment for cancer – Philadelphia Business Journal


KCTV Kansas City

Tooth banking: Is the next wave in stem cell treatment right for you?
KCTV Kansas City
For example, if your child or family member turned up with some sort of blood cancer, which is a common reason to turn to stem cell storage, Burgert says you won’t get any help from banked teeth. “Those stem cells that can be extracted from teeth are …

Continue reading

2017-10-19 Michael Zand NEWS

FDA approves 2nd gene therapy for blood cancer, this one for aggressive lymphoma in adults – Chicago Tribune

Chicago TribuneFDA approves 2nd gene therapy for blood cancer, this one for aggressive lymphoma in adultsChicago TribuneU.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lym… Continue reading

2017-10-19 Michael Zand NEWS

US regulators approve 2nd gene therapy for blood cancer – ABC News

ForbesUS regulators approve 2nd gene therapy for blood cancerABC NewsOn Wednesday, Oct. 18, 2017, the Food and Drug Administration approved sales of the therapy Yescarta, developed by Kite Pharma. It is the second gene therapy for U.S. patients _ the f… Continue reading

2017-10-19 Michael Zand NEWS

City of Hope, Leading Cancer Research and Treatment Center, to Provide First-Ever FDA-Approved CAR-T Cell … – Business Wire (press release)


Philadelphia Business Journal

FDA approves second gene-altering treatment for cancer
Philadelphia Business Journal
The treatment, considered a form of gene therapy, transforms the patient’s cells into what researchers call a “living drug” that attacks cancer cells. It is part of the rapidly growing field of immunotherapy, which uses drugs or genetic tinkering to …
US approves second gene therapy against cancerDeathRattleSports.com

all 8 news articles »

Continue reading

2017-10-19 Michael Zand NEWS

FDA Approves Axi-Cel for Large B-cell Lymphoma – Targeted Oncology

FDA Approves Axi-Cel for Large B-cell LymphomaTargeted OncologyThe FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed or refractory large B-cell lymphoma, making the agent the second approved … Continue reading

2017-10-19 Michael Zand NEWS

FDA Approves Second LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer Treatment – PR Newswire (press release)

FDA Approves Second LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer TreatmentPR Newswire (press release)The therapy, axicabtagene ciloleucel (Yescarta ™), is the second of this new method of treatment, known as CAR (chimeric … Continue reading

2017-10-19 Michael Zand NEWS
  • 1
  • …
  • 1,030
  • 1,031
  • 1,032
  • 1,033
  • 1,034
  • …
  • 3,595
Recent Posts
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Шведская компания ZandCell поставит 160 млн доз вакцины от COVID-19 в несколько стран мира 2021-07-22
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
Blog Categories
  • Anti-aging
  • Business
  • Google News RSS feed URL deprecation
  • NEWS
  • News Releases
  • Stem Cell Therapy
  • Veterinary
About Us

ZandCell is a biotechnology company pioneering the advancements and therapeutic applications of Stem Cell Therapy. Our Technology is called “Regenerate”.

SiteLock
Contact Info
+1-702-425-9049
+46-736-779970
info@zandcell.com
Find us on map


Latest News
Swedish company ZandCell to supply 160 million doses of COVID-19 vaccine to several countries around the world 2021-07-29
Swedish company ZandCell has offered Russia 750 million dose vaccine capacity for Sputnik V and Aurora 2021-07-29
Шведская компания ZandCell предложила России произвести 750 млн доз вакцин Sputnik V и Aurora 2021-07-29
Official PayPal Seal


© 2024 ZandCell. All Rights Reserved.
  • About
  • Programs
  • Science
  • Privacy Policy
  • Contact
  • RSS
  • Send us email
  • Follow us on Twitter
  • Follow us on Facebook
  • Follow Us on Linkedin
  • Call us via Skype
  • Follow Us on Instagram
  • Subscribe our YouTube Channel
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

City of Hope, Leading Cancer Research and Treatment Center, to Provide First-Ever FDA-Approved CAR–T Cell …
Business Wire (press release)
Axicabtagene ciloleucel, a Kite Pharma Inc. product, is a therapy in which a patient’s T cells are engineered to express a chimeric antigen receptor (CAR) to target the antigen CD19, a protein found on the cell surface of NHL as well as other lymphoma …

and more »